ClinicalTrials.gg
CompletedNCT00560508Updated Jul 31, 2014Results posted

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

A Phase 2/3 interventional study of Pramipexole Immediate Release and Pramipexole Extended Release in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 19 sites in Japan. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2014-07-31.

Sponsored by Boehringer Ingelheim · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
20th of 26
112 · median 224
Started
2007
with 4 others
Phase 2/3
Only one
of the 26
Registered
12th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 20th largest by enrollment, is one of 5 that started in 2007, is the only one in phase 2/3, and was the 12th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD on levodopa (L-DOPA) therapy (the double-blind period). The double-blind period will be followed by the open-label 52 week administration of pramipexole ER to evaluate the long term safety and efficacy (the open-label period).

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients with diagnosis of PD including juvenile Parkinsonism, in whom the onset began at the age of forty or younger.
  2. Patients with a modified Hoehn and Yahr scale of II to IV at "on" time.
  3. Patients who have received an individual dosage of L-DOPA (either standard L-DOPA or L-DOPA with dopa-decarboxylase inhibitor) at a stable dose for at least 4 weeks before the baseline visit (Visit 2).
  4. Patients who exhibit any therapeutically problematic issues or status based on L-DOPA therapy:

    • wearing-off phenomena
    • no on /delayed on
    • dystonia at off time
    • on-off phenomena
    • freezing phenomena at off time
    • the sub-optimal dose of L-DOPA had been administered due to side effects (such as dyskinesia), or therapeutical strategy

Exclusion criteria

Exclusion criteria

  1. Atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases.
  2. Dementia, as defined by a (MMSE) score \<24 at screening visit.
  3. Any psychiatric disorder according to criteria that could prevent compliance or completion of the trial and/or put the patient at risk if he/she takes part in the trial.
  4. History of psychosis, except history of drug induced hallucinations (provided the investigator considers that participation in the trial would not represent a significant risk for the patient).
  5. abnormalities at screening visit, according to investigator's judgement.
  6. Clinically significant hypotension or symptomatic orthostatic hypotension (i.e., clinical symptoms of orthostatic hypotension such as dizziness postural etc associated with a decline >=20 mmHg in systolic blood pressure and a decline >=10 mmHg in diastolic blood pressure, at one minute after standing compared with the previous supine systolic and diastolic blood pressure obtained after 5 minutes of quiet rest) either at screening visit or at baseline visit.
  7. Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the trial.
  8. Pregnancy (to be excluded by serum pregnancy test at screening visit) or breast-feeding.
  9. Sexually active female of not using a medically approved method of within one month before to the screening visit and throughout the trial period.
  10. Serum levels of , ALT, alkaline phosphatases or >2 .
  11. Patients with a \<50 mL/min
  12. Patients with a complication or signs of malignant tumours or those within 5 years after the treatment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Pramipexole Extended Release

    patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -\> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID

    Drug: Pramipexole Extended Release

  • Active comparator
    Pramipexole Immediate Release

    patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -\> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID

    Drug: Pramipexole Immediate Release

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced Adverse Events

    An adverse event is defined as any untoward medical occurrence

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score

    UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

    Time frame: baseline and after 12 weeks treatment

  2. Change From Baseline in Percentage Off-time

    Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

    Time frame: baseline and after 12 weeks treatment

  3. Change From Baseline in Percentage On-time Without Dyskinesia

    Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and after 12 weeks treatment

  4. Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia

    Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and after 12 weeks treatment

  5. Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia

    Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and after 12 weeks treatment

  6. Change From Baseline in Percentage On-time With Troublesome Dyskinesia

    Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and after 12 weeks treatment

  7. Responder Rate For Clinical Global Impression of Improvement (CGI-I)

    CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)

    Time frame: baseline and after 12 weeks treatment

  8. Responder Rate For Patient Global Impression of Improvement (PGI-I)

    PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring of 1 or 2 (at least much better)

    Time frame: baseline and after 12 weeks treatment

  9. Change From Baseline in UPDRS Part I Score

    UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood

    Time frame: baseline and after 12 weeks treatment

  10. Change From Baseline in UPDRS Part II Score

    UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.

    Time frame: baseline and after 12 weeks treatment

  11. Change From Baseline in UPDRS Part III Score

    UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms

    Time frame: baseline and after 12 weeks treatment

  12. Change From Baseline in UPDRS Part IV Score

    UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy

    Time frame: baseline and after 12 weeks treatment

  13. UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement)

    Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse

    Time frame: baseline and after 12 weeks treatment

  14. Change From Baseline in L-dopa Daily Dose

    The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.

    Time frame: baseline and after 12 weeks treatment

  15. Trough Plasma Concentration at Steady State

    Geometric mean (gMean) was calculated for trough plasma concentrations of pramipexole at steady state after administration of pramipexole IR 4.5mg and pramipexole ER 4.5mg.

    Time frame: at Visit 8 after pramipexole ER 4.5mg and IR 4.5mg treatment

  16. Dose Proportionality of Trough Plasma Concentration at Steady State After Pramipexole ER Treatment

    Dose proportionality of trough plasma concentrations at steady state is explored by using the power model that described the functional relationship between the dose and plasma concentration

    Time frame: from Visit 1 to Visit 8 after pramipexole ER

  17. Change From End of Double-Blind Period in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Dose Adjustment Phase)

    UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms. Least square means and standard errors presented are from ANCOVA with factors treatment and covariate baseline.

    Time frame: Week 12 to Week 16

  18. Percentage of Patients With no Worsening of UPDRS Parts II+III Total Score by More Than 15% From Week 12 to Week 16 (Open-label: Dose Adjustment Phase)

    Percentage of patients with no worsening of UPDRS Parts II+III Total Score by more than 15% from week 12 to week 16 (Open-label: Dose Adjustment Phase)

    Time frame: Week 12 to Week 16

  19. Clinical Global Impression of Improvement (CGI-I) at Week 16 Compared to Patient's CGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)

    Clinical Global Impression of Improvement (CGI-I) at week 16 compared to patient's CGI-I status at week 12. CGI-I scores ranging from '1' (very much improved) to '7' (very much worse)

    Time frame: Week 12 to Week 16

  20. Patient Global Impression of Improvement (PGI-I) at Week 16 Compared to Patient's PGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)

    Patient Global Impression of Improvement (PGI-I) at week 16 compared to patient's PGI-I status at week 12. PGI-I scores ranging from '1' (very much better) to '7' (very much worse).

    Time frame: Week 12 to Week 16

  21. Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Maintenance Phase)

    UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

    Time frame: Baseline and after 64 weeks treatment

  22. UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement) (Open-label: Maintenance Phase)

    Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse

    Time frame: baseline and after 64 weeks treatment

  23. Change From Baseline in Percentage Off-time (Open-label: Maintenance Phase)

    Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

    Time frame: baseline and after 64 weeks treatment

  24. Change From Baseline in Percentage On-time Without Dyskinesia (Open-label: Maintenance Phase)

    Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and after 64 weeks treatment

  25. Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia (Open-label Maintenance Phase)

    Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and after 64 weeks treatment

  26. Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia (Open-label Maintenance Phase)

    Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and after 64 weeks treatment

  27. Change From Baseline in Percentage On-time With Troublesome Dyskinesia (Open-label Maintenance Phase)

    Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and after 64 weeks treatment

  28. Change From Baseline in L-dopa Daily Dose (Open-label Maintenance Phase)

    The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.

    Time frame: baseline and after 64 weeks treatment

  29. Change From Baseline in UPDRS Part I Score (Open-label: Maintenance Phase)

    UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood

    Time frame: baseline and after 64 weeks treatment

  30. Change From Baseline in UPDRS Part II Score (Open-label: Maintenance Phase)

    UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.

    Time frame: baseline and after 64 weeks treatment

  31. Change From Baseline in UPDRS Part III Score (Open-label: Maintenance Phase)

    UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms

    Time frame: baseline and after 64 weeks treatment

  32. Change From Baseline in UPDRS Part IV Score (Open-label: Maintenance Phase)

    UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy

    Time frame: baseline and after 64 weeks treatment

07

Results

Posted Feb 10, 2011

Participant flow

12 Week Double-blind Period
Participant flow — 12 Week Double-blind Period
MilestonePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Started5656
Completed5153
Not completed53
Withdrew: Adverse event32
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject11
52-week Open-label Period Pramipexole ER
Participant flow — 52-week Open-label Period Pramipexole ER
MilestonePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Started5153
Completed4342
Not completed811
Withdrew: Adverse event66
Withdrew: Lack of efficacy11
Withdrew: Withdrawal by subject03
Withdrew: Other reason - investigator's judgement11

Outcome measures

SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score

UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · UPDRS scores on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score
UPDRS scores on a scalePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score-13.6 ± 1.3-13.3 ± 1.3
SecondaryChange From Baseline in Percentage Off-time

Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · Percentage of off-time
Change From Baseline in Percentage Off-time
Percentage of off-timePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in Percentage Off-time-5.8 ± 2.4-7.8 ± 2.4
SecondaryChange From Baseline in Percentage On-time Without Dyskinesia

Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time Without Dyskinesia
Percentage of on-timePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in Percentage On-time Without Dyskinesia6.4 ± 2.57.0 ± 2.5
SecondaryChange From Baseline in Percentage On-time With Non-troublesome Dyskinesia

Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia
Percentage of on-timePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia-0.4 ± 0.40.1 ± 0.4
SecondaryChange From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia

Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia
Percentage of on-timePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia6.0 ± 2.57.1 ± 2.5
SecondaryChange From Baseline in Percentage On-time With Troublesome Dyskinesia

Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time With Troublesome Dyskinesia
Percentage of on-timePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in Percentage On-time With Troublesome Dyskinesia-0.1 ± 0.50.5 ± 0.5
SecondaryResponder Rate For Clinical Global Impression of Improvement (CGI-I)

CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)

Time frame:
baseline and after 12 weeks treatment
Reported as:
Number · percentage of participants
Responder Rate For Clinical Global Impression of Improvement (CGI-I)
percentage of participantsPramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Responder Rate For Clinical Global Impression of Improvement (CGI-I)48.250.0
SecondaryResponder Rate For Patient Global Impression of Improvement (PGI-I)

PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring of 1 or 2 (at least much better)

Time frame:
baseline and after 12 weeks treatment
Reported as:
Number · percentage of participants
Responder Rate For Patient Global Impression of Improvement (PGI-I)
percentage of participantsPramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Responder Rate For Patient Global Impression of Improvement (PGI-I)33.933.9
SecondaryChange From Baseline in UPDRS Part I Score

UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · UPDRS scores on a scale
Change From Baseline in UPDRS Part I Score
UPDRS scores on a scalePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in UPDRS Part I Score0.1 ± 0.2-0.2 ± 0.2
SecondaryChange From Baseline in UPDRS Part II Score

UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · UPDRS scores on a scale
Change From Baseline in UPDRS Part II Score
UPDRS scores on a scalePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in UPDRS Part II Score-3.3 ± 0.4-3.4 ± 0.4
SecondaryChange From Baseline in UPDRS Part III Score

UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · UPDRS scores on a scale
Change From Baseline in UPDRS Part III Score
UPDRS scores on a scalePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in UPDRS Part III Score-10.2 ± 1.0-9.9 ± 1.0
SecondaryChange From Baseline in UPDRS Part IV Score

UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · UPDRS scores on a scale
Change From Baseline in UPDRS Part IV Score
UPDRS scores on a scalePramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in UPDRS Part IV Score-0.2 ± 0.2-0.4 ± 0.2
SecondaryUPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement)

Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse

Time frame:
baseline and after 12 weeks treatment
Reported as:
Number · percentage of participants
UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement)
percentage of participantsPramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement)78.682.1
SecondaryChange From Baseline in L-dopa Daily Dose

The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.

Time frame:
baseline and after 12 weeks treatment
Reported as:
Least squares mean · mg per day
Change From Baseline in L-dopa Daily Dose
mg per dayPramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Change From Baseline in L-dopa Daily Dose-5.3 ± 3.0-1.8 ± 3.0
PrimaryPercentage of Participants Who Experienced Adverse Events

An adverse event is defined as any untoward medical occurrence

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Adverse Events
percentage of participantsPramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Percentage of Participants Who Experienced Adverse Events83.9383.93
SecondaryTrough Plasma Concentration at Steady State

Geometric mean (gMean) was calculated for trough plasma concentrations of pramipexole at steady state after administration of pramipexole IR 4.5mg and pramipexole ER 4.5mg.

Time frame:
at Visit 8 after pramipexole ER 4.5mg and IR 4.5mg treatment
Reported as:
Geometric mean · ng/ml
Trough Plasma Concentration at Steady State
ng/mlPramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
Trough Plasma Concentration at Steady State5.46 ± 2.015.09 ± 2.53
SecondaryDose Proportionality of Trough Plasma Concentration at Steady State After Pramipexole ER Treatment

Dose proportionality of trough plasma concentrations at steady state is explored by using the power model that described the functional relationship between the dose and plasma concentration

Time frame:
from Visit 1 to Visit 8 after pramipexole ER
Reported as:
Mean · ng/mL
Dose Proportionality of Trough Plasma Concentration at Steady State After Pramipexole ER Treatment
ng/mLPramipexole Extended Release Group (PPX ER)
Dose Proportionality of Trough Plasma Concentration at Steady State After Pramipexole ER Treatment1.0375 ± 0.0177
SecondaryChange From End of Double-Blind Period in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Dose Adjustment Phase)

UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms. Least square means and standard errors presented are from ANCOVA with factors treatment and covariate baseline.

Time frame:
Week 12 to Week 16
Reported as:
Least squares mean · UPDRS scores on a scale
Change From End of Double-Blind Period in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Dose Adjustment Phase)
UPDRS scores on a scaleFrom PPX ER to PPX ERFrom PPX IR to PPX ER
Change From End of Double-Blind Period in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Dose Adjustment Phase)-2.2 ± 0.6-0.2 ± 0.6
SecondaryPercentage of Patients With no Worsening of UPDRS Parts II+III Total Score by More Than 15% From Week 12 to Week 16 (Open-label: Dose Adjustment Phase)

Percentage of patients with no worsening of UPDRS Parts II+III Total Score by more than 15% from week 12 to week 16 (Open-label: Dose Adjustment Phase)

Time frame:
Week 12 to Week 16
Reported as:
Number · percentage of participants
Percentage of Patients With no Worsening of UPDRS Parts II+III Total Score by More Than 15% From Week 12 to Week 16 (Open-label: Dose Adjustment Phase)
percentage of participantsFrom PPX ER to PPX ERFrom PPX IR to PPX ER
Percentage of Patients With no Worsening of UPDRS Parts II+III Total Score by More Than 15% From Week 12 to Week 16 (Open-label: Dose Adjustment Phase)78.483.0
SecondaryClinical Global Impression of Improvement (CGI-I) at Week 16 Compared to Patient's CGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)

Clinical Global Impression of Improvement (CGI-I) at week 16 compared to patient's CGI-I status at week 12. CGI-I scores ranging from '1' (very much improved) to '7' (very much worse)

Time frame:
Week 12 to Week 16
Reported as:
Number · percentage of participants
Clinical Global Impression of Improvement (CGI-I) at Week 16 Compared to Patient's CGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)
percentage of participantsFrom PPX ER to PPX ERFrom PPX IR to PPX ER
Very much improved0.01.9
Much improved8.05.7
Minimally improved48.035.8
No change34.050.9
Minimally worse10.05.7
SecondaryPatient Global Impression of Improvement (PGI-I) at Week 16 Compared to Patient's PGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)

Patient Global Impression of Improvement (PGI-I) at week 16 compared to patient's PGI-I status at week 12. PGI-I scores ranging from '1' (very much better) to '7' (very much worse).

Time frame:
Week 12 to Week 16
Reported as:
Number · percentage of participants
Patient Global Impression of Improvement (PGI-I) at Week 16 Compared to Patient's PGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)
percentage of participantsFrom PPX ER to PPX ERFrom PPX IR to PPX ER
Very much better2.03.8
Much better14.011.3
A little better36.035.8
No change36.039.6
A little worse12.09.4
SecondaryChange From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Maintenance Phase)

UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

Time frame:
Baseline and after 64 weeks treatment
Reported as:
Mean · UPDRS scores on a scale
Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Maintenance Phase)
UPDRS scores on a scalePramipexole ER: Open-Label Phase
Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Maintenance Phase)-15.2 ± 11.1
SecondaryUPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement) (Open-label: Maintenance Phase)

Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse

Time frame:
baseline and after 64 weeks treatment
Reported as:
Number · percentage of participants
UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement) (Open-label: Maintenance Phase)
percentage of participantsPramipexole ER: Open-Label Phase
UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement) (Open-label: Maintenance Phase)92.0
SecondaryChange From Baseline in Percentage Off-time (Open-label: Maintenance Phase)

Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

Time frame:
baseline and after 64 weeks treatment
Reported as:
Mean · Percentage of off-time
Change From Baseline in Percentage Off-time (Open-label: Maintenance Phase)
Percentage of off-timePramipexole ER: Open-Label Phase
Change From Baseline in Percentage Off-time (Open-label: Maintenance Phase)-11.6 ± 22.1
SecondaryChange From Baseline in Percentage On-time Without Dyskinesia (Open-label: Maintenance Phase)

Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and after 64 weeks treatment
Reported as:
Mean · Percentage of on-time
Change From Baseline in Percentage On-time Without Dyskinesia (Open-label: Maintenance Phase)
Percentage of on-timePramipexole ER: Open-Label Phase
Change From Baseline in Percentage On-time Without Dyskinesia (Open-label: Maintenance Phase)11.9 ± 21.1
SecondaryChange From Baseline in Percentage On-time With Non-troublesome Dyskinesia (Open-label Maintenance Phase)

Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and after 64 weeks treatment
Reported as:
Mean · Percentage of on-time
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia (Open-label Maintenance Phase)
Percentage of on-timePramipexole ER: Open-Label Phase
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia (Open-label Maintenance Phase)-0.1 ± 5.7
SecondaryChange From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia (Open-label Maintenance Phase)

Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and after 64 weeks treatment
Reported as:
Mean · Percentage of on-time
Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia (Open-label Maintenance Phase)
Percentage of on-timePramipexole ER: Open-Label Phase
Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia (Open-label Maintenance Phase)11.8 ± 21.6
SecondaryChange From Baseline in Percentage On-time With Troublesome Dyskinesia (Open-label Maintenance Phase)

Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and after 64 weeks treatment
Reported as:
Mean · Percentage of on-time
Change From Baseline in Percentage On-time With Troublesome Dyskinesia (Open-label Maintenance Phase)
Percentage of on-timePramipexole ER: Open-Label Phase
Change From Baseline in Percentage On-time With Troublesome Dyskinesia (Open-label Maintenance Phase)-0.2 ± 2.8
SecondaryChange From Baseline in L-dopa Daily Dose (Open-label Maintenance Phase)

The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.

Time frame:
baseline and after 64 weeks treatment
Reported as:
Mean · mg per day
Change From Baseline in L-dopa Daily Dose (Open-label Maintenance Phase)
mg per dayPramipexole ER: Open-Label Phase
Change From Baseline in L-dopa Daily Dose (Open-label Maintenance Phase)10.3 ± 62.0
SecondaryChange From Baseline in UPDRS Part I Score (Open-label: Maintenance Phase)

UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood

Time frame:
baseline and after 64 weeks treatment
Reported as:
Mean · UPDRS scores on a scale
Change From Baseline in UPDRS Part I Score (Open-label: Maintenance Phase)
UPDRS scores on a scalePramipexole ER: Open-Label Phase
Change From Baseline in UPDRS Part I Score (Open-label: Maintenance Phase)-0.3 ± 1.5
SecondaryChange From Baseline in UPDRS Part II Score (Open-label: Maintenance Phase)

UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.

Time frame:
baseline and after 64 weeks treatment
Reported as:
Mean · UPDRS scores on a scale
Change From Baseline in UPDRS Part II Score (Open-label: Maintenance Phase)
UPDRS scores on a scalePramipexole ER: Open-Label Phase
Change From Baseline in UPDRS Part II Score (Open-label: Maintenance Phase)-3.4 ± 4.2
SecondaryChange From Baseline in UPDRS Part III Score (Open-label: Maintenance Phase)

UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms

Time frame:
baseline and after 64 weeks treatment
Reported as:
Least squares mean · UPDRS scores on a scale
Change From Baseline in UPDRS Part III Score (Open-label: Maintenance Phase)
UPDRS scores on a scalePramipexole ER: Open-Label Phase
Change From Baseline in UPDRS Part III Score (Open-label: Maintenance Phase)-11.9 ± 8.2
SecondaryChange From Baseline in UPDRS Part IV Score (Open-label: Maintenance Phase)

UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy

Time frame:
baseline and after 64 weeks treatment
Reported as:
Mean · UPDRS scores on a scale
Change From Baseline in UPDRS Part IV Score (Open-label: Maintenance Phase)
UPDRS scores on a scalePramipexole ER: Open-Label Phase
Change From Baseline in UPDRS Part IV Score (Open-label: Maintenance Phase)-0.6 ± 1.6

Adverse events

Collected over From the first dose of trial medication onwards through the observational phase (64 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pramipexole Extended Release Group (PPX ER)—12/56 (21.4%)52/56 (92.9%)
Pramipexole Immediate Release Group (PPX IR)—10/56 (17.9%)49/56 (87.5%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
DehydrationMetabolism and nutrition disorders2/560/56
Parkinson's diseaseNervous system disorders1/562/56
Inguinal herniaGastrointestinal disorders2/560/56
Posture abnormalMusculoskeletal and connective tissue disorders1/562/56
PneumoniaInfections and infestations0/561/56
PyelonephritisInfections and infestations1/560/56
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/560/56
Disseminated intravascular coagulationBlood and lymphatic system disorders1/560/56
DelusionPsychiatric disorders1/561/56
Hallucination, visualPsychiatric disorders1/561/56
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)
SomnolenceNervous system disorders21/5620/56
NasopharyngitisInfections and infestations18/5618/56
ConstipationGastrointestinal disorders7/5612/56
Back painMusculoskeletal and connective tissue disorders8/5611/56
NauseaGastrointestinal disorders8/5610/56
FallInjury, poisoning and procedural complications7/5610/56
DyskinesiaNervous system disorders9/564/56
DizzinessNervous system disorders8/564/56
Hallucination, visualPsychiatric disorders7/567/56
Orthostatic hypotensionVascular disorders7/565/56

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)Total
Mean68.8 ± 8.066.1 ± 7.567.5 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Pramipexole Extended Release Group (PPX ER)Pramipexole Immediate Release Group (PPX IR)Total
Female353570
Male212142
08

Study locations

19 sites
  • 248.610.019 Boehringer Ingelheim Investigational Site
    Akashi, Hyogo, Japan
  • 248.610.020 Boehringer Ingelheim Investigational Site
    Akita, Akita, Japan
  • 248.610.006 Boehringer Ingelheim Investigational Site
    Aomori, Aomori, Japan
  • 248.610.017 Boehringer Ingelheim Investigational Site
    Asahikawa, Hokkaido, Japan
  • 248.610.018 Boehringer Ingelheim Investigational Site
    Asahikawa, Hokkaido, Japan
  • 248.610.001 Boehringer Ingelheim Investigational Site
    Bunkyo-ku, Tokyo, Japan
  • 248.610.014 Boehringer Ingelheim Investigational Site
    Fuchu, Tokyo, Japan
  • 248.610.011 Boehringer Ingelheim Investigational Site
    Fukuoka, Fukuoka, Japan
  • 248.610.015 Boehringer Ingelheim Investigational Site
    Iwamizawa,Hokkaido, Japan
  • 248.610.003 Boehringer Ingelheim Investigational Site
    Kodaira, Tokyo, Japan
  • 248.610.008 Boehringer Ingelheim Investigational Site
    Kyoto, Kyoto, Japan
  • 248.610.021 Boehringer Ingelheim Investigational Site
    Kyoto, Kyoto, Japan
  • 248.610.010 Boehringer Ingelheim Investigational Site
    Morioka, Iwate, Japan
  • 248.610.005 Boehringer Ingelheim Investigational Site
    Okayama, Okayama, Japan
  • 248.610.012 Boehringer Ingelheim Investigational Site
    Osaka, Osaka, Japan
  • 248.610.004 Boehringer Ingelheim Investigational Site
    Sagamihara, Kanagawa, Japan
  • 248.610.009 Boehringer Ingelheim Investigational Site
    Shimogyo-ku, Kyoto, Kyoto, Japan
  • 248.610.007 Boehringer Ingelheim Investigational Site
    Shiroishi, Miyagi, Japan
  • 248.610.002 Boehringer Ingelheim Investigational Site
    Takamatsu, Kagawa, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007 and a primary completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2007
First posted
Nov 19, 2007
Start
Nov 2007
Primary completionActual
Nov 2009
Results first posted
Feb 10, 2011
Last update
Jul 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00560508
Responsible party
Sponsor
First posted
Nov 19, 2007
Start date
Nov 2007
Primary completion
Nov 2009
Results posted
Feb 10, 2011
Last update
Jul 31, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion